CANBERA (dpa-AFX) - Telix Pharmaceuticals Limited (TLX, TLX.AX) reported that its operating profit for the first-half of 2025 dropped to US$10.4 million from US$27.7 million in the prior year.
Loss before tax was US$4.8 million compared to profit of US$22.9 million in the prior year. The latest period results included US$12.4 million in non-cash finance costs associated with convertible bonds issued in July 2024 and increased amortization cot of US$9.5 million following RLS acquisition.
Revenue for the period was US$390.4 million, up 63% from last year.
Telix confirmed fiscal year 2025 revenue guidance of US$770 million to US$800 million.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
Copyright(c) 2025 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2025 AFX News
